Autologous CAR T cells targeting NKG2D ligands therapy(Leucid Bio)

N/A

Report date: 2024/01/08 17:08:34

Base Information

Drug NameAutologous CAR T cells targeting NKG2D ligands therapy(Leucid Bio)

Drug Alias NameNKG2D CAR T-cell therapy (Leucid Bio)LEU-011LEU011LEU01101LEU-01101

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Donor > Autologous

Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsNKG2D ligands modulators

TargetsNKG2D ligands

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited Kingdom

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesLeucid Bio

China Registration ClassN/A

Develop Information

Active CompaniesLeucid Bio

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A